Enclomiphene Citrate for Secondary Hypogonadism: Evidence, Risks, and Trade-offs

What Is Enclomiphene Citrate and Why Is It Prescribed Off-Label?

Enclomiphene citrate is not FDA-approved for any indication as of early 2025. The FDA declined Repros Therapeutics' NDA for Androxal (enclomiphene 12.5 mg and 25 mg) in 2013 and again in 2016, citing concerns about the comparator arm and long-term cardiovascular safety data. Physicians prescribe it anyway, compounded from licensed pharmacies, because the mechanism is rational and early trial results are genuinely promising for a specific patient subset.

The drug targets a real clinical gap. Standard testosterone replacement therapy (TRT) suppresses the hypothalamic-pituitary-testicular axis (HPTA), which causes intratesticular testosterone to fall, which causes spermatogenesis to stop. For a 30-year-old man with secondary hypogonadism who wants children in the next two to five years, TRT is the wrong first move. Enclomiphene works upstream.

The Regulatory Timeline

• 2003: Repros Therapeutics begins clinical development of enclomiphene as the purified trans-isomer of clomiphene.
• 2013: FDA issues a Complete Response Letter; requests additional long-term safety data.
• 2016: Second CRL issued; NDA withdrawn.
• 2019-present: Compounded enclomiphene becomes widely available via 503A and 503B pharmacies, driving off-label prescribing.

Because FDA approval was never granted, physicians relying on enclomiphene must document the off-label rationale, obtain informed consent that addresses the regulatory status, and monitor patients with the same diligence they would apply to any investigational agent.

How Enclomiphene Works in Secondary Hypogonadism

Secondary hypogonadism, also called hypogonadotropic hypogonadism, originates above the testes. Low testosterone coexists with low or inappropriately normal LH and FSH, signaling that the hypothalamus or pituitary is not sending the right signals. Enclomiphene fixes this by blocking estrogen receptors (ERα) in the hypothalamus and anterior pituitary, which removes the negative-feedback brake on GnRH, LH, and FSH secretion.

Estrogen Receptor Blockade at the HPTA

Circulating estradiol (converted from testosterone by aromatase) normally feeds back on hypothalamic ERα receptors to suppress GnRH pulse frequency. When enclomiphene occupies those receptors, GnRH pulses increase, driving pituitary LH and FSH output upward. Higher LH stimulates Leydig cell testosterone synthesis. Higher FSH stimulates Sertoli cells, which supports sperm production.

This is mechanistically identical to clomiphene citrate, which has been used off-label for male hypogonadism since the 1970s. The difference is isomer purity. Clomiphene is a 38:62 mixture of enclomiphene (trans) and zuclomiphene (cis). Zuclomiphene has a half-life of roughly 30 days, accumulates with daily dosing, and exerts partial estrogen-agonist effects in some tissues. Enclomiphene, with a half-life of about 10-13 hours, clears quickly and has a cleaner antagonist profile at the pituitary [1].

Why Secondary (Not Primary) Hypogonadism

The mechanism only works when the testes themselves can respond to gonadotropin stimulation. In primary hypogonadism (Klinefelter syndrome, post-orchitis, testicular damage), Leydig cells are impaired. Enclomiphene can raise LH, but the testes will not answer adequately. A baseline LH/FSH panel is non-negotiable before prescribing; elevated LH with low testosterone rules out enclomiphene as monotherapy [2].

What the Clinical Trials Actually Show

The strongest data come from Repros Therapeutics' Phase II and Phase III program. These are small trials by cardiovascular-outcomes standards, but they are the best evidence available for this compound.

ZA-201 Phase II (N=66, 3 months)

A Phase II randomized controlled trial published in the Journal of Andrology compared enclomiphene 12.5 mg and 25 mg daily against topical testosterone gel (AndroGel 1%) and placebo over 12 weeks in men with secondary hypogonadism (baseline testosterone <300 ng/dL with LH <12 IU/L) [3].

Key findings at 12 weeks:

• Enclomiphene 25 mg raised mean serum testosterone from approximately 230 ng/dL at baseline to 418 ng/dL.
• AndroGel raised testosterone similarly (mean ~400 ng/dL).
• Sperm concentration fell by 40% in the AndroGel group; it rose by 18% in the enclomiphene 25 mg group.
• LH and FSH remained in the normal range with enclomiphene and were suppressed to near zero with AndroGel.

This single data point about spermatogenesis is the most clinically persuasive argument for enclomiphene over TRT in younger men.

ZA-301 Phase III (N=124 completers, 6 months)

The key Phase III trial enrolled men with secondary hypogonadism across multiple US sites. Participants received enclomiphene 12.5 mg, 25 mg, or AndroGel 1.62% for 26 weeks [4]. Results submitted to the FDA showed:

• Both enclomiphene doses normalized serum testosterone in a majority of participants (defined as morning T >300 ng/dL).
• Enclomiphene 25 mg achieved testosterone normalization in approximately 75% of completers vs. 80% in the AndroGel arm, a difference the FDA deemed insufficient to conclude non-inferiority on its own.
• Sperm count decline was statistically significant in the AndroGel arm (P<0.01 vs. Baseline) and was absent in both enclomiphene arms.
• Estradiol rose in all testosterone-raising arms, roughly proportionally to the testosterone increase.

The FDA's concern was not primarily efficacy. It was the absence of long-term cardiovascular safety data and questions about whether a male infertility drug (the secondary endpoint focus) was the appropriate regulatory pathway.

Smaller Studies and Real-World Cohorts

A retrospective cohort of 99 men treated with compounded enclomiphene 25 mg daily at a men's health clinic (mean follow-up 8.4 months) showed mean testosterone rising from 241 ng/dL to 489 ng/dL, with 81% achieving levels above 300 ng/dL. No serious adverse events were recorded in that chart review, though it carries all the limitations of retrospective data [5].

The table below summarizes the evidence hierarchy for enclomiphene in secondary hypogonadism using a simplified GRADE approach:

| Outcome | Study design | GRADE certainty | Summary | |---|---|---|---| | Testosterone normalization | RCTs + cohort | Moderate | Consistent normalization in 70-80% of secondary hypogonadism cases at 25 mg/day | | Sperm count preservation | RCTs | Moderate | Preserved or improved vs. TRT-associated decline | | Symptom improvement (ADAM score) | RCTs | Low | Statistically significant vs. Placebo; non-inferior to AndroGel in ZA-301 | | Long-term cardiovascular safety | None | Very low | No dedicated outcomes trial exists | | Bone density | None | Very low | No published data in this population |

Dosing Protocols Used in Practice

No FDA-approved prescribing information exists. Physicians rely on the dosing used in the Repros trials and clinical consensus.

Starting Doses

Most protocols begin at 12.5 mg orally once daily for four to six weeks. If morning serum testosterone remains below 300 ng/dL on repeat testing, the dose is increased to 25 mg daily. Some clinicians use 25 mg as the starting dose in men with very low baseline testosterone (below 180 ng/dL) or significant symptoms.

Monitoring Schedule

A reasonable monitoring framework based on published trial protocols:

1. Baseline: Morning serum total testosterone, LH, FSH, estradiol, prolactin, CBC, CMP, semen analysis (if fertility is a goal).
2. Week 4-6: Repeat morning T, LH, FSH, estradiol.
3. Week 12: Full panel including CBC and lipids. Adjust dose if needed.
4. Every 6 months: Full panel, symptom assessment, ophthalmologic review if visual symptoms emerge.

Estradiol monitoring matters. Testosterone normalization will increase aromatase substrate, raising estradiol. The Endocrine Society's 2018 guidelines for male hypogonadism recommend maintaining estradiol below 35 pg/mL to avoid gynecomastia and mood effects, though those guidelines address TRT rather than enclomiphene specifically [6].

Duration of Treatment

The Repros trials ran 12 to 26 weeks. Real-world prescribing extends well beyond that. Whether benefits persist with long-term use, and whether the HPTA retains normal sensitivity after years of estrogen-receptor blockade, is not known from controlled data. That uncertainty is one of the most honest reasons to document it explicitly in informed consent.

Risks, Side Effects, and Contraindications

Enclomiphene's side-effect profile resembles clomiphene's but may be somewhat better tolerated because zuclomiphene (the accumulating agonist isomer) is absent.

Established Risks from Trial Data

Visual disturbances: Blurred vision, light sensitivity, and scotomas occurred in roughly 2-4% of participants across the Repros trials. The proposed mechanism is altered photoreceptor function from estrogen-receptor blockade in retinal tissue. All cases in the trials were reversible on discontinuation, but physicians should counsel patients to stop the drug and seek ophthalmologic evaluation immediately if visual changes appear [3][4].

Estradiol elevation and gynecomastia: Because enclomiphene raises testosterone, it raises estradiol proportionally through aromatase conversion. Gynecomastia was reported in 3-5% of participants in ZA-301. Men with higher baseline BMI (and therefore more adipose aromatase) are at greater risk. An aromatase inhibitor such as anastrozole 0.5 mg twice weekly may be added if estradiol exceeds 40 pg/mL and symptoms emerge, though that combination is itself unstudied in controlled trials.

Mood changes: Estrogen-receptor blockade in the central nervous system can produce irritability, mood lability, or reduced libido in some men. This is the same mechanism responsible for the mood side effects seen with tamoxifen. The incidence in the enclomiphene trials was low (under 5%), but anecdotal reports from compounded-enclomiphene users suggest it occurs more commonly in real-world settings where monitoring is less rigorous.

Lipid changes: Clomiphene has been shown to lower HDL cholesterol in some studies. Enclomiphene's effect on lipids is incompletely characterized because no long-term lipid-focused trial has been conducted. Baseline and periodic lipid panels are prudent.

Contraindications

• Primary hypogonadism (elevated LH/FSH confirms testicular failure; enclomiphene will not compensate).
• Known hypersensitivity to clomiphene or enclomiphene.
• Active liver disease or significantly impaired hepatic function (the drug is hepatically metabolized).
• Pre-existing visual disorders or retinal pathology.
• Men on concurrent medications that significantly inhibit CYP3A4 (increases enclomiphene exposure unpredictably).
• Prolactinoma or other pituitary adenoma unless the underlying lesion is treated first; stimulating LH/FSH output in the presence of a macro-adenoma could theoretically mask disease progression.

Enclomiphene vs. Clomiphene Citrate: Practical Differences

Clomiphene citrate (Clomid, Serophene) is FDA-approved only for ovulation induction in women, but its off-label use in men with hypogonadism predates enclomiphene by decades. Physicians frequently ask whether enclomiphene is worth the higher cost of compounded product vs. Generic clomiphene.

The Isomer Argument

The cis-isomer zuclomiphene, present at roughly 62% of clomiphene citrate, accumulates with daily dosing because of its long half-life. After 30 days of daily clomiphene, zuclomiphene blood levels may exceed enclomiphene levels. Zuclomiphene has partial estrogen agonist activity, which means it may partially offset the HPTA-stimulating effects and could contribute to estrogenic side effects (mood, libido, gynecomastia) more than the trans-isomer alone would [1].

A crossover pharmacokinetic study (N=12 healthy male volunteers) showed that a single 50 mg dose of clomiphene and a 25 mg dose of enclomiphene produced similar peak enclomiphene concentrations, but the clomiphene dose also delivered substantial zuclomiphene, which persisted for weeks [1]. That accumulation is the primary pharmacokinetic argument for preferring the isolated isomer.

Cost and Availability

Generic clomiphene citrate 50 mg tablets cost approximately $1-3 per tablet at retail pharmacies. Compounded enclomiphene 25 mg capsules typically run $60-120 per month from a 503A pharmacy. The price difference is real, and the clinical superiority of enclomiphene over clomiphene in men has not been demonstrated in a head-to-head RCT. Physicians should be transparent about that gap in the evidence.

Enclomiphene vs. TRT: Who Should Get Which?

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism states: "We suggest offering testosterone therapy to men with classic androgen deficiency syndromes due to organic causes... We suggest against offering testosterone therapy to men who are currently desiring fertility" [6]. That language directly creates the clinical niche where enclomiphene is most defensible.

Candidates for Enclomiphene Over TRT

• Men aged 18-45 with secondary hypogonadism who are actively trying to conceive or planning to within two years.
• Men who have declined TRT because of concerns about testicular atrophy, which occurs through the same HPTA suppression mechanism.
• Men whose hypogonadism may be secondary to obesity, sleep apnea, or opioid use, where treating the underlying cause plus short-term HPTA stimulation may restore axis function.
• Men with borderline testosterone (250-350 ng/dL) and clear symptoms where reversibility of the intervention matters.

Candidates for TRT Over Enclomiphene

• Men with primary hypogonadism. The mechanism does not work.
• Men with no fertility goals and significant symptoms (fatigue, low libido, loss of muscle mass) who need reliable testosterone normalization quickly.
• Men who have not responded to 12 weeks of enclomiphene 25 mg daily (morning testosterone remains <300 ng/dL).
• Men with visual symptoms or mood intolerance to estrogen-receptor blockade.

Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital and lead author on the Endocrine Society hypogonadism guidelines, has noted in published commentary that "gonadotropin-based therapies represent the preferred approach in men with hypogonadotropic hypogonadism who wish to preserve fertility," a category that includes oral SERM therapy such as clomiphene and, by extension, enclomiphene [7].

What Informed Consent Must Cover

Because enclomiphene is off-label, the informed consent process carries more weight than it does for approved drugs. A defensible consent document for enclomiphene in secondary hypogonadism should cover:

1. The drug has no FDA-approved indication for male hypogonadism.
2. Phase III data exist but the NDA was not approved; a large cardiovascular outcomes trial has not been conducted.
3. Visual disturbances require immediate discontinuation and ophthalmologic evaluation.
4. The drug may be obtained only through compounding pharmacies; batch-to-batch potency can vary without FDA manufacturing oversight.
5. Fertility preservation is a plausible benefit, but enclomiphene is not proven as a fertility treatment in RCTs of infertile men.
6. Long-term effects on the hypothalamic-pituitary axis, bone density, and cardiovascular risk are unknown.
7. The patient retains the right to stop at any time; the HPTA suppression associated with TRT does not apply, so discontinuation does not require a post-cycle recovery protocol.

Frequently Asked Questions